Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism GABAA receptor modulators(Gamma-aminobutyric acid A receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC3H5FN2O6 |
InChIKeyHKUPDUFVYVLELI-UHFFFAOYSA-N |
CAS Registry220046-01-5 |
Start Date17 Dec 2018 |
Sponsor / Collaborator Gabather AB [+1] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Behavioural disorders | Phase 1 | - | - | |
Behavioural disorders | Phase 1 | - | - | |
Behavioural disorders | Phase 1 | - | - | |
Cognitive Dysfunction | Preclinical | SE | 21 Aug 2024 | |
Dementia | Preclinical | SE | 21 Aug 2024 | |
Schizophrenia | Preclinical | FI | 17 Dec 2018 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
PRNewswire Manual | Phase 1 | - | - | (dndmtelvdi) = Clinically relevant effects of GT-002 were observed on modulation of EEG frequency band power with a significant increase in alpha band power, compared to Lorazepam at the 2-hour after treatment. This effect spanned various brain regions, including frontal and occipital areas.
No significant effect of Lorazepam on EEG alpha band power compared to placebo was observed. nkskalvcay (mzcczzflri ) | - | 07 Mar 2024 | |